TRCT
CYCN icon

Tower Research Capital (TRC)’s Cyclerion Therapeutics CYCN Stock Holding History

Tower Research Capital (TRC)’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,154
Closed -$4.01K – 5189
2025
Q4 		$4.01K Buy
3,154
+826
+35% +$1.48K ﹤0.01% 4273
2025
Q3 		$5.35K Sell
2,328
-435
-16% -$1.18K ﹤0.01% 4241
2025
Q2 		$8.04K Buy
2,763
+1,709
+162% +$5.1K ﹤0.01% 4026
2025
Q1 		$2.63K Sell
1,054
-1,387
-57% -$4.13K ﹤0.01% 4521
2024
Q4 		$7.86K Buy
2,441
+1,363
+126% +$3.79K ﹤0.01% 4036
2024
Q3 		$2.79K Sell
1,078
-386
-26% -$1.14K ﹤0.01% 4936
2024
Q2 		$3.37K Buy
1,464
+1,431
+4,336% +$4.07K ﹤0.01% 4897
2024
Q1 		$106 Buy
+33
New +$105 ﹤0.01% 5651
2023
Q2 		– Sell
-664
Closed -$6K – 6087
2023
Q1 		$6K Sell
664
-164
-20% -$2.07K ﹤0.01% 4833
2022
Q4 		$11K Buy
828
+376
+83% +$4.45K ﹤0.01% 3802
2022
Q3 		$8K Sell
452
-226
-33% -$3.88K ﹤0.01% 4770
2022
Q2 		$8K Sell
678
-195
-22% -$2.79K ﹤0.01% 4665
2022
Q1 		$19K Sell
873
-264
-23% -$6.36K ﹤0.01% 3571
2021
Q4 		$39K Sell
1,137
-300
-21% -$14.2K ﹤0.01% 2967
2021
Q3 		$88K Buy
+1,437
New +$94K ﹤0.01% 2505
2021
Q2 		– Sell
-335
Closed -$19K – 5524
2021
Q1 		$19K Buy
335
+64
+24% +$4.81K ﹤0.01% 3911
2020
Q4 		$17K Sell
271
-949
-78% -$64.7K ﹤0.01% 3958
2020
Q3 		$148K Buy
1,220
+961
+371% +$110K ﹤0.01% 2829
2020
Q2 		$31K Buy
259
+113
+77% +$9.45K ﹤0.01% 3414
2020
Q1 		$8K Buy
+146
New +$10.4K ﹤0.01% 2111
2019
Q4 		– Sell
-189
Closed -$46K – 3676
2019
Q3 		$46K Buy
189
+68
+56% +$14.7K ﹤0.01% 1850
2019
Q2 		$28K Buy
+121
New +$34.2K ﹤0.01% 1940

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tower Research Capital (TRC)'s CYCN Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Cyclerion Therapeutics (CYCN) in Q1 2026, closing a stake of 3,154 shares — an estimated $4.01K sold.

Tower Research Capital (TRC) first reported a position in CYCN in Q2 2019 and held it in 22 quarters. The position peaked at $148K in Q3 2020. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Cyclerion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,154 Cyclerion Therapeutics shares in Q1 2026, an estimated $4.01K.
  • Tower Research Capital (TRC) first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 22 quarters.
  • Tower Research Capital (TRC)'s Cyclerion Therapeutics position peaked at $148K in Q3 2020.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.